Mucinous Adenocarcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: MCN001 MIFTS: 49	Mucinous Adenocarcinoma Categories: Cancer diseases
Genes Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Mucinous Adenocarcinoma

MalaCards integrated aliases for Mucinous Adenocarcinoma:

Name: Mucinous Adenocarcinoma ¹² ¹⁵ ⁷⁰

Mucin-Producing Adenocarcinoma ¹² ⁷⁰

Pseudomyxoma Peritonei with Unknown Primary Site ¹²

Mucin-Secreting Adenocarcinoma ¹²

Mucin-Secreting Carcinoma ¹²

Adenocarcinoma, Mucinous ⁴⁴

Mucous Carcinoma ¹²

Classifications:

MalaCards categories:
Global: Cancer diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:3030

MeSH ⁴⁴ D002288

NCIt ⁵⁰ C26712 C27379

SNOMED-CT ⁶⁷ 72495009 900006

UMLS ⁷⁰ C0007130 C0334368

Sources

Summaries for Mucinous Adenocarcinoma

Disease Ontology : ¹² An adenocarcinoma that derives from epithelial cells originating in glandular tissue, which produce mucin.

MalaCards based summary : Mucinous Adenocarcinoma, also known as mucin-producing adenocarcinoma, is related to appendix adenocarcinoma and endometrial mucinous adenocarcinoma. An important gene associated with Mucinous Adenocarcinoma is CHST4 (Carbohydrate Sulfotransferase 4), and among its related pathways/superpathways are ERK Signaling and Endometrial cancer. The drugs Oxaliplatin and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include lung, colon and appendix, and related phenotypes are Decreased viability and Decreased viability

Sources

Related Diseases for Mucinous Adenocarcinoma

Diseases related to Mucinous Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 737)

#	Related Disease	Score	Top Affiliating Genes
1	appendix adenocarcinoma	33.1	KRT7 KRT20 KRAS CDX2
2	endometrial mucinous adenocarcinoma	32.8	PGR MUC1 CDKN2A
3	cervical adenoma malignum	32.5	TP53 PGR KRT7 CDX2
4	bile duct mucinous adenocarcinoma	32.4	TP53 MUC5AC MUC1
5	ovarian mucinous adenocarcinoma	32.4	MUC5AC KRT7 KRT20 CEACAM5 CDX2
6	mucinous stomach adenocarcinoma	32.2	NKX2-1 KRT7 CDX2
7	pseudomyxoma peritonei	31.6	TP53 MUC5AC MUC1 KRT7 KRT20 KRAS
8	urachal adenocarcinoma	31.4	KRAS CEACAM5
9	intestinal obstruction	30.9	KRT7 KRT20 CEACAM5 CDX2
10	anus adenocarcinoma	30.8	MUC5AC KRT7 CDX2
11	rectum cancer	30.8	MLH1 KRT20 KRAS CEACAM5
12	clear cell adenocarcinoma	30.7	TP53 KRT7 KRT20
13	bladder adenocarcinoma	30.6	KRT7 KRT20 ERBB2 CDX2
14	mucinous lung adenocarcinoma	30.6	NRG1 NKX2-1 KRAS
15	sertoli-leydig cell tumor	30.6	PGR MUC1 KRT7
16	anal canal adenocarcinoma	30.5	MUC5AC KRT7 KRT20 CEACAM5 CDX2
17	teratoma	30.5	TP53 NKX2-1 KRT7 KRT20 KRAS CEACAM5
18	vaginal discharge	30.5	PGR ESR1 CEACAM5
19	transverse colon cancer	30.5	MLH1 KRT7 KRT20 KRAS CEACAM5
20	adenocarcinoma in situ	30.4	KRT7 KRT20 KRAS EGFR CEACAM5 CDX2
21	neuroendocrine carcinoma	30.4	NKX2-1 MUC1 KRT7 KRT20 CEACAM5
22	mucinous cystadenocarcinoma	30.4	MUC1 KRT7 KRT20 CEACAM5
23	lymphangitis	30.4	NKX2-1 CEACAM5 ALK
24	cystic teratoma	30.4	TP53 NKX2-1 MUC5AC KRT7 KRT20 KRAS
25	cystadenoma	30.4	PGR MUC5AC MUC1 KRT7 KRT20 CEACAM5
26	eyelid carcinoma	30.3	KRT7 KRT20
27	mature teratoma	30.3	TP53 KRT7 KRAS ERBB2 CEACAM5
28	jejunal neoplasm	30.3	KRT7 KRT20
29	gastrointestinal carcinoma	30.3	TP53 MUC1 KRT20 CEACAM5 CDX2
30	descending colon cancer	30.3	KRAS CEACAM5 CDX2
31	bile duct cysts	30.3	KRT7 KRAS CEACAM5
32	eccrine papillary adenocarcinoma	30.3	PGR KRT7 CEACAM5
33	thymus adenocarcinoma	30.3	KRT20 CEACAM5 CDX2
34	gallbladder adenocarcinoma	30.3	TP53 KRT20 ERBB2 EGFR
35	ovarian large-cell neuroendocrine carcinoma	30.3	KRT7 KRT20
36	adenosquamous colon carcinoma	30.3	MLH1 KRT7 CDX2
37	ovarian germ cell cancer	30.3	NKX2-1 KRT7 CEACAM5
38	serous cystadenocarcinoma	30.3	TP53 PGR KRAS ERBB2
39	horseshoe kidney	30.3	NKX2-1 KRT7 KRT20 EGFR CDX2
40	benign mesothelioma	30.3	NKX2-1 KRT7 KRT20 CEACAM5 CDKN2A
41	ovarian mucinous neoplasm	30.3	MUC5AC KRT7 KRT20 KRAS CEACAM5 CDX2
42	adenocarcinoma	30.3	TP53 NKX2-1 MUC1 MLH1 KRT7 KRT20
43	adenoma	30.2	TP53 MUC5AC MUC1 MLH1 KRT7 KRT20
44	mammary analogue secretory carcinoma	30.2	TP53 MUC1 EGFR
45	krukenberg carcinoma	30.2	KRT7 KRT20 CEACAM5 CDX2
46	cystadenocarcinoma	30.2	TP53 PGR MUC5AC MUC1 KRT7 ERBB2
47	pancreatic adenocarcinoma	30.1	TP53 KRAS ERBB2 EGFR CDKN2A
48	mammary paget's disease	30.1	PGR MUC1 KRT7 KRT20 ESR1 ERBB2
49	prostatic hypertrophy	30.1	PGR ESR1 EGFR
50	benign teratoma	30.1	TP53 NKX2-1 MUC1 KRT7 KRT20 CEACAM5

Graphical network of the top 20 diseases related to Mucinous Adenocarcinoma:

Sources

Symptoms & Phenotypes for Mucinous Adenocarcinoma

GenomeRNAi Phenotypes related to Mucinous Adenocarcinoma according to GeneCards Suite gene sharing:

²⁶ (show all 13)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased viability	GR00055-A-1	9.92	EGFR KRAS
2	Decreased viability	GR00055-A-2	9.92	EGFR KRAS
3	Decreased viability	GR00055-A-3	9.92	KRAS
4	Decreased viability	GR00106-A-0	9.92	KRAS
5	Decreased viability	GR00221-A-1	9.92	ALK CDKN2A EGFR ESR1 KRAS
6	Decreased viability	GR00221-A-2	9.92	ESR1 KRAS
7	Decreased viability	GR00221-A-3	9.92	CDKN2A ERBB2
8	Decreased viability	GR00221-A-4	9.92	ALK CDKN2A EGFR ESR1 ERBB2
9	Decreased viability	GR00249-S	9.92	ALK
10	Decreased viability	GR00301-A	9.92	KRAS
11	Decreased viability	GR00381-A-1	9.92	KRAS
12	Decreased viability	GR00386-A-1	9.92	ESR1
13	Decreased viability	GR00402-S-2	9.92	ESR1

MGI Mouse Phenotypes related to Mucinous Adenocarcinoma:

⁴⁶ (show all 13)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cellular	MP:0005384	10.34	CDKN2A CDX2 CHST4 EGFR ERBB2 ESR1
2	homeostasis/metabolism	MP:0005376	10.3	ALK CDKN2A CDX2 EGFR ERBB2 ESR1
3	endocrine/exocrine gland	MP:0005379	10.26	ALK CDKN2A CDX2 EGFR ERBB2 ESR1
4	digestive/alimentary	MP:0005381	10.21	CDKN2A CDX2 EGFR ERBB2 ESR1 KRAS
5	embryo	MP:0005380	10.15	CDKN2A CDX2 EGFR ERBB2 ESR1 HNF4A
6	neoplasm	MP:0002006	10.11	ALK CDKN2A CDX2 EGFR ERBB2 ESR1
7	integument	MP:0010771	10.09	ALK CDKN2A EGFR ERBB2 ESR1 KRAS
8	normal	MP:0002873	9.96	ALK CDX2 EGFR ERBB2 ESR1 HNF4A
9	limbs/digits/tail	MP:0005371	9.95	CDX2 EGFR ERBB2 ESR1 KRAS PGR
10	reproductive system	MP:0005389	9.9	ALK CDKN2A CDX2 EGFR ERBB2 ESR1
11	no phenotypic analysis	MP:0003012	9.87	CDKN2A EGFR ESR1 KRAS NKX2-1 PGR
12	respiratory system	MP:0005388	9.61	ALK CDKN2A EGFR ERBB2 ESR1 KRAS
13	skeleton	MP:0005390	9.32	ALK CDKN2A CDX2 EGFR ERBB2 ESR1

Sources

Drugs & Therapeutics for Mucinous Adenocarcinoma

Drugs for Mucinous Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 119)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Oxaliplatin

Approved, Investigational

Phase 3

61825-94-3

5310940 9887054 43805 6857599

Carboplatin

Approved

Phase 3

41575-94-4

10339178 498142 38904

Cisplatin

Approved

Phase 3

15663-27-1

84093 441203 2767

Gemcitabine

Approved

Phase 3

95058-81-4

60750

Docetaxel

Approved, Investigational

Phase 3

114977-28-5

148124

Glutamic acid

Approved, Nutraceutical

Phase 3

56-86-0

33032

Camptothecin

Experimental

Phase 3

7689-03-4

Edrecolomab

Experimental, Investigational

Phase 3

156586-89-9

Paclitaxel poliglumex

Experimental, Investigational

Phase 3

263351-82-2

Micronutrients

Phase 3

Trace Elements

Phase 3

Carotenoids

Phase 3

Adjuvants, Immunologic

Phase 3

Immunosuppressive Agents

Phase 3

Antimetabolites

Phase 3

Hematinics

Phase 3

Anti-Infective Agents

Phase 3

Antiviral Agents

Phase 3

taxane

Phase 3

Panitumumab

Approved, Investigational

Phase 2

339177-26-3

50070211

Nintedanib

Approved

Phase 2

656247-17-5

56843413

Xylometazoline

Approved, Investigational

Phase 2

526-36-3

5709

Iodine

Approved, Investigational

Phase 2

7553-56-2

807

Ipilimumab

Approved

Phase 2

477202-00-9

nivolumab

Approved

Phase 2

946414-94-4

Talimogene laherparepvec

Approved, Experimental, Investigational

Phase 2

1187560-31-1

Turmeric

Approved, Experimental, Investigational

Phase 2

Curcumin

Approved, Experimental, Investigational

Phase 2

458-37-7

969516

Capecitabine

Approved, Investigational

Phase 2

154361-50-9

60953

Cyclophosphamide

Approved, Investigational

Phase 2

50-18-0, 6055-19-2

2907

Pembrolizumab

Approved

Phase 2

1374853-91-4

Olaparib

Approved

Phase 2

763113-22-0

23725625

Topotecan

Approved, Investigational

Phase 2

123948-87-8, 119413-54-6

60700

Durvalumab

Approved, Investigational

Phase 2

1428935-60-7

Acetylcysteine

Approved, Investigational

Phase 1, Phase 2

616-91-1

12035

Irinotecan

Approved, Investigational

Phase 2

100286-90-6, 97682-44-5

60838

Fluorouracil

Approved

Phase 1, Phase 2

51-21-8

3385

Levoleucovorin

Approved, Investigational

Phase 2

68538-85-2

149436

leucovorin

Approved

Phase 2

58-05-9

6006

Indomethacin

Approved, Investigational

Phase 1, Phase 2

53-86-1

3715

Gefitinib

Approved, Investigational

Phase 2

184475-35-2

123631

Tyrosine

Approved, Investigational, Nutraceutical

Phase 2

60-18-4

6057

Folic acid

Approved, Nutraceutical, Vet_approved

Phase 2

59-30-3

6037

Cediranib

Investigational

Phase 2

288383-20-0

9933475

Maleic acid

Experimental

Phase 2

110-16-7

444266

Fluorodeoxyglucose F18

Phase 2

Radiopharmaceuticals

Phase 2

Immunoglobulin Fc Fragments

Phase 2

Pharmaceutical Solutions

Phase 2

Apatinib

Phase 1, Phase 2

811803-05-1

Interventional clinical trials:

(show top 50) (show all 63)

#	Name	Status	NCT ID	Phase	Drugs
1	Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?	Unknown status	NCT00719303	Phase 3
2	A Randomized Phase III Equivalence Trial of Irinotecan (CPT-11) Versus Oxaliplatin (OXAL)/5-Fluorouracil (5-FU)/Leucovorin (CF) in Patients With Advanced Colorectal Carcinoma Previously Treated With 5-FU	Completed	NCT00005036	Phase 3	irinotecan hydrochloride;oxaliplatin;leucovorin calcium;fluorouracil
3	Intergroup Randomized Phase III Study of Postoperative Irinotecan, 5-Fluorouracil and Leucovorin vs. Oxaliplatin, 5-Fluorouracil and Leucovorin vs. 5-Fluorouracil and Leucovorin for Patients With Stage II or III Rectal Cancer Receiving Either Preoperative Radiation and 5-Fluorouracil or Postoperative Radiation and 5-Fluorouracil	Completed	NCT00068692	Phase 3	Fluorouracil;Leucovorin Calcium;Oxaliplatin;Irinotecan
4	Phase III Randomized Study of Adjuvant Immunotherapy With Monoclonal Antibody 17-1A Versus No Adjuvant Therapy Following Resection for State II (Modified Astler-Coller B2) Adenocarcinoma of the Colon	Completed	NCT00002968	Phase 3
5	A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC # 704865) Followed by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women With Newly Diagnosed, Previously Untreated, Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer	Completed	NCT00262847	Phase 3	Carboplatin;Paclitaxel
6	A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin Versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients With Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers	Active, not recruiting	NCT00217737	Phase 3	Fluorouracil;Leucovorin Calcium;Oxaliplatin
7	GOG-0262: A Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel in Combination With Carboplatin With or Without Concurrent and Consolidation Bevacizumab (NSC #704865) in the Treatment of Primary Stage II, III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer and ACRIN 6695: Perfusion CT Imaging to Evaluate Treatment Response in Patients Participating in GOG-0262	Active, not recruiting	NCT01167712	Phase 3	Carboplatin;Paclitaxel
8	A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12, Monthly Cycles of Single Agent Paclitaxel or CT-2103 Versus No Treatment Until Documented Relapse in Women With Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy	Active, not recruiting	NCT00108745	Phase 3	Paclitaxel;Paclitaxel Poliglumex
9	A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)	Active, not recruiting	NCT00565851	Phase 3	Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel
10	A Phase III Clinical Trial of Bevacizumab With IV Versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma	Active, not recruiting	NCT00951496	Phase 3	Carboplatin;Carboplatin;Cisplatin;Paclitaxel;Paclitaxel
11	A Phase II Study of Panitumumab in Combination With FOLFIRI After Progression on FOLFIRI Plus Bevacizumab in KRAS(Kirsten Rat Sarcoma) and NRAS Wild-Type Metastatic Colorectal Cancer.	Unknown status	NCT01814501	Phase 2	irinotecan hydrochloride;fluorouracil;leucovorin calcium
12	A Phase II Study of the Combination of Aflibercept (VEGF-Trap) Plus Modified FOLFOX 6 in Patients With Previously Untreated Metastatic Colorectal Cancer	Unknown status	NCT01652196	Phase 2	oxaliplatin;leucovorin;fluorouracil
13	Is Greater Downstaging and Tumour Regression Observed When Surgery is Delayed to 12 Weeks After Completion of Chemoradiotherapy vs 6 Weeks?	Unknown status	NCT01037049	Phase 2
14	A Phase 2 Study of MK-2206 in Previously Treated Metastatic Colorectal Cancer Patients Enriched for PTEN Loss and PIK3CA Mutation	Completed	NCT01802320	Phase 2	Akt Inhibitor MK2206
15	Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer	Completed	NCT00100841	Phase 2	oxaliplatin;leucovorin calcium;fluorouracil
16	A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma	Completed	NCT01225887	Phase 2	Nintedanib
17	A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma	Completed	NCT01642082	Phase 2
18	A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer	Completed	NCT00888615	Phase 2	Elesclomol Sodium;Paclitaxel
19	A Phase II Evaluation of Brivanib (BMS582664), an Oral, Multitargeted Growth Factor Tyrosine Kinase Inhibitor in the Treatment of Recurrent or Persistent Endometrial Carcinoma	Completed	NCT00888173	Phase 2	Brivanib Alaninate
20	A Clinical Study of Exploring Camrelizumab in the Treatment of Colorectal Mucinous Adenocarcinoma(MAC)	Recruiting	NCT04446091	Phase 1, Phase 2	Carilizumab + anti-angiogenic TKIs (available with fuquitinib, rigofenib, apatinib, etc.);Carilizumab + anti-angiogenic TKIs (available with fuquitinib, rigofenib, apatinib, etc.)+Irinotecan
21	MC1365, A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer	Recruiting	NCT02364713	Phase 2	Gemcitabine Hydrochloride;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
22	DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors	Recruiting	NCT02834013	Phase 2
23	A Phase I-II, FIH Study of A166 in Locally Advanced/Metastatic Solid Tumors Expressing Human Epidermal Growth Factor Receptor 2 (HER2) or Are HER2 Amplified That Did Not Respond or Stopped Responding to Approved Therapies	Recruiting	NCT03602079	Phase 1, Phase 2	A166
24	A Phase II Study of Talimogene Laherparepvec Followed by Talimogene Laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors	Recruiting	NCT02978625	Phase 2
25	Phase I/II Trial of Intraperitoneal Administration of Adipose Tissue Derived Mesenchymal Stem Cells Infected With a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent Ovarian Cancer	Recruiting	NCT02068794	Phase 1, Phase 2
26	Phase II Trial Of Neoadjuvant Bevacizumab With Modified FOLFOX7 In Patients With Stage II And III Rectal Cancer	Active, not recruiting	NCT01871571	Phase 2	oxaliplatin;leucovorin calcium;fluorouracil
27	A Randomized Double Blinded Study of Curcumin With Pre-operative Capecitabine and Radiation Therapy Followed by Surgery for Rectal Cancer	Active, not recruiting	NCT00745134	Phase 2	Capecitabine
28	A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus	Active, not recruiting	NCT00492778	Phase 2	Cisplatin
29	A Phase II Evaluation of Pembrolizumab in Combination With IV Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Active, not recruiting	NCT02853318	Phase 2	Cyclophosphamide
30	A Phase II Trial of Bevacizumab With Carboplatin and Weekly Paclitaxel as First-Line Treatment in Epithelial Ovarian, Primary Peritoneal, and Fallopian Tube Carcinoma	Active, not recruiting	NCT01097746	Phase 2	Carboplatin;Paclitaxel
31	A Randomized Phase II Induction Discontinuation Trial of Emactuzumab Following Paclitaxel and Bevacizumab in Patients With Platinum-Resistant, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Active, not recruiting	NCT02923739	Phase 2	Paclitaxel
32	A Randomized Phase II Trial of Triplet Therapy (a PD-L1 Inhibitor MEDI4736 (Durvalumab) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or MEDI4736 (Durvalumab) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab	Not yet recruiting	NCT04739800	Phase 2	Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
33	Injection of Bromelain and Acetylcysteine in Combination Into Recurrent Mucinous Tumour or Pseudomyxoma Peritonei	Not yet recruiting	NCT03976973	Phase 1, Phase 2	Bromelain, Stem;Acetylcysteine
34	Phase I-II Study of Fluorouracil in Combination With Phenylbutyrate, Indomethacin and Recombinant Human Interferon-Gamma in Advanced Colorectal Cancer	Terminated	NCT00002796	Phase 1, Phase 2	fluorouracil;sodium phenylbutyrate;indomethacin
35	A Phase II Trial Of IRESSA (NSC 715055, IND 61187) In Combination With 5-FU/LV/ CPT-11 In Patients With Advanced Or Recurrent Colorectal Cancer	Terminated	NCT00052585	Phase 2	irinotecan hydrochloride;gefitinib;leucovorin calcium;fluorouracil
36	Phase II Study of Drug-eluting Irinotecan Beads (DEBIRI) in Refractory Metastatic Colorectal Cancer With Liver-only or Liver-predominant Disease	Terminated	NCT01285102	Phase 2
37	Phase II Study of Ziv-Aflibercept Followed by the Addition of 5-FU in the Third Line Setting of Metastatic Colorectal Cancer	Withdrawn	NCT02235324	Phase 2	leucovorin calcium;fluorouracil
38	A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal Cancer	Completed	NCT00060411	Phase 1	erlotinib hydrochloride;fluorouracil;leucovorin calcium;oxaliplatin
39	Phase I Study of the Combination of Irinotecan and MLN8237 in Advanced Solid Tumors With Emphasis on Colorectal Cancer	Completed	NCT01923337	Phase 1	irinotecan hydrochloride;alisertib
40	Phase I Study of Preoperative Radiation Therapy With Concurrent Protracted Continuous Infusion 5-FU and Dose Escalating Oxaliplatin Followed by Surgery, 5-FU, and Leucovorin for Locally Advanced (T3 and T4) Rectal Adenocarcinoma	Completed	NCT00003799	Phase 1	fluorouracil;oxaliplatin;leucovorin calcium
41	Pilot and Translational Study of Dasatinib (NSC#732517) Paclitaxel and Carboplatin in Women With Advanced Stage and Recurrent Endometrial Cancer	Completed	NCT01440998	Phase 1	Carboplatin;Dasatinib;Paclitaxel
42	A Phase I Pharmacokinetic Study of Intraperitoneal CTEP-Supplied Agent Bortezomib (PS-341, NSC 681239) and Carboplatin (NSC# 241240) in Patients With Persistent or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Completed	NCT01074411	Phase 1	Bortezomib;Carboplatin
43	A Genotype-guided Dosing Study of mFOLFIRINOX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies	Completed	NCT01643499	Phase 1	oxaliplatin;irinotecan hydrochloride;leucovorin calcium;fluorouracil
44	Phase 1 With Expansion Cohorts in a Study of NEO-201 in Adults With Chemo-Resistant Solid Tumors	Recruiting	NCT03476681	Phase 1	NEO-201
45	Phase I Trial of Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy With Nanoliposomal Irinotecan in Patients With Peritoneal Surface Malignancies	Recruiting	NCT04088786	Phase 1	nanoliposomal irinotecan
46	A Phase I Clinical Trial of Fluorouracil (5-FU) + CPI-613 Combination in Previously Treated Metastatic Colorectal Cancer Patients	Active, not recruiting	NCT02232152	Phase 1	6,8-bis(benzylthio)octanoic acid;fluorouracil
47	Phase I Study of Neoadjuvant Short Course Radiotherapy Concurrent With Infusional 5-Fluorouracil for the Treatment of Locally Advanced Rectal Cancer	Active, not recruiting	NCT02270606	Phase 1	fluorouracil;oxaliplatin;leucovorin calcium
48	A Phase I Study of Intravenous Carboplatin/Paclitaxel or Intravenous and Intraperitoneal Paclitaxel/Cisplatin in Combination With Continuous or Intermittent /CTEP-Supplied Agent ABT-888 (NSC #737664) and CTEP-Supplied Agent Bevacizumab (NSC #704865) in Newly Diagnosed Patients With Previously Untreated Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer	Active, not recruiting	NCT00989651	Phase 1	Carboplatin;Cisplatin;Paclitaxel;Veliparib
49	A Phase I/Ib Dose Escalation Study of Pegylated Liposomal Doxorubicin (PLD) With Peposertib (M3814) in Platinum - Resistant or Ineligible Ovarian and Related Cancers With Planned Expansions in High Grade Serous (HGSOC) and Low Grade Serous Ovarian Cancer (LGSOC)	Suspended	NCT04092270	Phase 1	Pegylated Liposomal Doxorubicin Hydrochloride;Peposertib
50	Targeted Complex Therapy for Advanced Melanoma, Gynecologic Cancers, and Other Malignancies: Nab-Paclitaxel (Abraxane)/Bevacizumab Complex (AB-Complex)	Suspended	NCT02020707	Phase 1	Nab-paclitaxel

Search NIH Clinical Center for Mucinous Adenocarcinoma

Cochrane evidence based reviews: adenocarcinoma, mucinous

Sources

Genetic Tests for Mucinous Adenocarcinoma

Sources

Anatomical Context for Mucinous Adenocarcinoma

MalaCards organs/tissues related to Mucinous Adenocarcinoma:

⁴⁰

Lung, Colon, Appendix, Prostate, Ovary, Liver, Cervix

Sources

Publications for Mucinous Adenocarcinoma

Articles related to Mucinous Adenocarcinoma:

(show top 50) (show all 2353)

#	Title	Authors	PMID	Year
1	Consensus molecular subtyping of colorectal cancers is influenced by goblet cell content. ⁶¹	Miller SA...O'Hagan HM	33571895	2021
2	Development of a mucinous adenocarcinoma on a sigmoid colpoplasty for vaginal agenesis: About a case report and review of the literature. ⁶¹	Christophe M...Lambaudie E	33786358	2021
3	Colorectal cancer under 20 years old: a retrospective analysis from three tertiary hospitals. ⁶¹	Zhou C...Gao Y	32968876	2021
4	Clinicopathological, molecular features and prognosis of colorectal cancer with mucinous component. ⁶¹	Li J...Deng Y	33331169	2021
5	Diffuse expression of MUC6 defines a distinct clinicopathological subset of pulmonary invasive mucinous adenocarcinoma. ⁶¹	Kishikawa S...Yao T	33024306	2021
6	Mucinous adenocarcinoma caused by cancerization from a ciliated multinodular papilloma tumor: A case report. ⁶¹	Chen F...Chen J	33811447	2021
7	Snowball-like appearance on radial endobronchial ultrasonography in a patient with invasive mucinous adenocarcinoma. ⁶¹	Kawaguchi T...Marutsuka K	33732468	2021
8	Colitis cystica profunda mimicking mucinous adenocarcinoma of the rectum diagnosed by endoscopic submucosal dissection. ⁶¹	Abe T...Murakami K	32818983	2021
9	Primary Invasive Mucinous Adenocarcinoma of the Lung: Prognostic Value of CT Imaging Features Combined with Clinical Factors. ⁶¹	Wang T...Chen C	33236544	2021
10	Comprehensive analysis of the clinicopathological features, targetable profile, and prognosis of mucinous adenocarcinoma of the lung. ⁶¹	Ueda D...Okada M	33796913	2021
11	Synaptophysin expression in V600EBRAF-mutated advanced colorectal cancers identifies a new subgroup of tumours with worse prognosis. ⁶¹	Fassan M...Loupakis F	33607478	2021
12	Genetic characteristics of gastric-type mucinous carcinoma of the uterine cervix. ⁶¹	Park E...Cho NH	32641744	2021
13	Excellent Prognosis of Patients With Invasive Lung Adenocarcinomas During Surgery Misdiagnosed as Atypical Adenomatous Hyperplasia, Adenocarcinoma In Situ, or Minimally Invasive Adenocarcinoma by Frozen Section. ⁶¹	Zhang Y...Chen H	33197404	2021
14	[A Case of Gastric Cancer Which Caused Severe Anemia(Hemoglobin 1.8 g/dL)]. ⁶¹	Konishi K...Hirano S	33790158	2021
15	Nanog maintains stemness of Lkb1-deficient lung adenocarcinoma and prevents gastric differentiation. ⁶¹	Tong X...Ji H	33439550	2021
16	Current Microsatellite Instability Testing in Management of Colorectal Cancer. ⁶¹	Sun BL	32888812	2021
17	Clinicopathological characteristics and survival outcomes for patients with mucinous colorectal cancer liver metastases undergoing hepatic resection: A systematic review and meta-analysis. ⁶¹	Reynolds IS...Hoti E	33750573	2021
18	A case report of multiple bilateral breast metastases after colorectal cancer. ⁶¹	Arnaout K...Ayoub K	33743246	2021
19	Breast cancer detection by dedicated breast positron emission tomography according to the World Health Organization classification of breast tumors. ⁶¹	Sasada S...Okada M	33685728	2021
20	Is the Effect of Tumor Localization on Prognosis Compatible with Real-life Data in Metastatic Colon Cancer? Single-Center Experience: A Retrospective Analysis. ⁶¹	Oytun MG...Gokmen E	33665720	2021
21	Combined fibrinogen-to-pre-albumin ratio and carbohydrate antigen 19-9 score is a promising metric to predict progression of metastatic colorectal mucinous adenocarcinoma. ⁶¹	Liao YC...Cheng XX	33734488	2021
22	A novel TNIP2-RET fusion identified in a patient with mucinous adenocarcinoma of the lung. ⁶¹	Ren P...Jin M	33478856	2021
23	Incidental Finding of Primary Mucinous Adenocarcinoma of Gall Bladder: a Histopathological Diagnosis. ⁶¹	Bharti S...Anju G	32529395	2021
24	Treating the treatment: chemotherapy-induced multi-organ toxicity. ⁶¹	Tyebally S...Ghosh AK	33722912	2021
25	Clinicopathological characteristics and survival in lung signet ring cell carcinoma: a population-based study. ⁶¹	Cai Y...Meng S	33596400	2021
26	Invasive mucinous adenocarcinoma of the lung arising in a type 1 congenital pulmonary airway malformation in a 68-year-old patient: a case report. ⁶¹	Frick AE...Van Raemdonck D	31262240	2021
27	Acinar with ductal and mucinous adenocarcinoma of prostate cancer complicated with lung metastasis: a case report and literature review. ⁶¹	Cui Y...Liu B	32576002	2021
28	Is 99m Tc bone scintigraphy necessary in the preoperative workup for patients with cT1N0 subsolid lung cancer? A prospective multicenter cohort study. ⁶¹	Li H...Chen H	33210466	2021
29	The Utility of Preoperative Tumor Markers in Peritoneal Carcinomatosis from Primary Appendiceal Adenocarcinoma: an Analysis from the US HIPEC Collaborative. ⁶¹	Fackche N...Greer JB	33634422	2021
30	A case of Endometrioid endometrial adenocarcinoma with synchronous low-grade Appendiceal mucinous neoplasm and Pseudomyxoma peritonei. ⁶¹	Raje S...Rao G	33605928	2021
31	A case of primary adenocarcinoma of the seminal vesicle treated by total laparoscopic pelvic exenteration. ⁶¹	Tochigi K...Gotoh M	32854127	2021
32	Development and validation of a nomogram for predicting survival of pulmonary invasive mucinous adenocarcinoma based on surveillance, epidemiology, and end results (SEER) database. ⁶¹	Wang Y...Du J	33568091	2021
33	Mucinous Adenocarcinoma With Intrapulmonary Metastasis Harboring KRAS and GNAS Mutations Arising in Congenital Pulmonary Airway Malformation. ⁶¹	de Cordova XF...Liang J	33609098	2021
34	Comparative study of imaging and pathological evaluation of pneumonic mucinous adenocarcinoma. ⁶¹	Han J...Xue X	33552246	2021
35	Mucinous adenocarcinoma arising in congenital pulmonary airway malformation: clinicopathological analysis of 37 cases. ⁶¹	Chang WC...Nicholson AG	32810914	2021
36	Salivary Mucinous Adenocarcinoma Is a Histologically Diverse Single Entity With Recurrent AKT1 E17K Mutations: Clinicopathologic and Molecular Characterization With Proposal for a Unified Classification. ⁶¹	Rooper LM...Bishop JA	33739781	2021
37	Cervical Adenoma Malignum in Third Trimester Pregnancy. ⁶¹	Pannecoeck K...De Visschere P	33506174	2021
38	Pseudomyxoma pleurii: unusual location of a rare disease. ⁶¹	Imrani K...Omor Y	33294092	2021
39	Therapeutic Potential of Afatinib in NRG1 Fusion-Driven Solid Tumors: A Case Series. ⁶¹	Cadranel J...Renouf DJ	32852072	2021
40	Mapping of colorectal carcinoma diseases with activation of Wnt/beta-catenin signalling pathway using hierarchical clustering approach. ⁶¹	Mosnier JF...Denis M	33441391	2021
41	Chemotherapy for Non-Small Cell Lung Cancer in the Intensive Care Unit. ⁶¹	Nasser A...Wheatley-Price P	33383487	2021
42	The expression of trefoil factor 3 is related to histologic subtypes and invasiveness in lung adenocarcinoma. ⁶¹	Luo W...Morii E	33281974	2021
43	Stratification of Stage III colon cancer may identify a patient group not requiring adjuvant chemotherapy. ⁶¹	Malik YG...Ignjatovic D	32924067	2021
44	A Prognostic Nomogram of Colon Cancer With Liver Metastasis: A Study of the US SEER Database and a Chinese Cohort. ⁶¹	Liu C...Wen T	33738248	2021
45	Clinicopathological and Molecular Features of Colorectal Cancer Patients With Mucinous and Non-Mucinous Adenocarcinoma. ⁶¹	Lan YT...Yang SH	33738258	2021
46	Risk of Second Primary Malignancies Based on the Histological Subtypes of Colorectal Cancer. ⁶¹	Wu M...Chu X	33777813	2021
47	Thirty-three long-term survivors after cytoreductive surgery in patients with peritoneal metastases from colorectal cancer: a retrospective descriptive study. ⁶¹	Kamada Y...Yonemura Y	33509224	2021
48	Clinical, endoscopic and histological profile of colorectal cancers seen on colonoscopy in Kano, North-Western Nigeria. ⁶¹	Musa Y...Borodo MM	33642320	2021
49	A Case Report: Cutaneous Metastasis of Advanced Rectal Cancer with BRAF Mutation. ⁶¹	Zhou S...Fu J	33603403	2021
50	Late Development of Metastatic Ovarian Mucinous Adenocarcinoma From Primary Gallblader Adenocarcinoma and High-grade Dysplasia. ⁶¹	Taylor J...McCluggage WG	32897957	2021

Sources

Genes for Mucinous Adenocarcinoma

Genes related to Mucinous Adenocarcinoma (0 elite genes):

(show all 27)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	CHST4	Carbohydrate Sulfotransferase 4	Protein Coding	20.4	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Expressions (show sections)
2	KRT7	Keratin 7	Protein Coding	15.13	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
3	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	14.93	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
4	CDX2	Caudal Type Homeobox 2	Protein Coding	14.74	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
5	CEACAM5	CEA Cell Adhesion Molecule 5	Protein Coding	14.14	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
6	KRT20	Keratin 20	Protein Coding	14.07	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
7	NKX2-1	NK2 Homeobox 1	Protein Coding	13.96	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
8	MUC5AC	Mucin 5AC, Oligomeric Mucus/Gel-Forming	Protein Coding	13.79	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
9	MUC1	Mucin 1, Cell Surface Associated	Protein Coding	13.53	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
10	EGFR	Epidermal Growth Factor Receptor	Protein Coding	13.51	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
11	TP53	Tumor Protein P53	Protein Coding	13.38	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
12	MLH1	MutL Homolog 1	Protein Coding	13.31	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
13	ALK	ALK Receptor Tyrosine Kinase	Protein Coding	13.3	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
14	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	13.01	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
15	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	12.94	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
16	NRG1	Neuregulin 1	Protein Coding	12.84	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
17	PGR	Progesterone Receptor	Protein Coding	12.79	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
18	HNF4A	Hepatocyte Nuclear Factor 4 Alpha	Protein Coding	12.24	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
19	ESR1	Estrogen Receptor 1	Protein Coding	12.15	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
20	CHST5	Carbohydrate Sulfotransferase 5	Protein Coding	11.93	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
21	KIT	KIT Proto-Oncogene, Receptor Tyrosine Kinase	Protein Coding	11.84	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
22	VEGFA	Vascular Endothelial Growth Factor A	Protein Coding	11.82	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
23	KRT19	Keratin 19	Protein Coding	11.75	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
24	MUC16	Mucin 16, Cell Surface Associated	Protein Coding	11.72	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
25	SLC3A2	Solute Carrier Family 3 Member 2	Protein Coding	10.98	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
26	AMACR	Alpha-Methylacyl-CoA Racemase	Protein Coding	10.74	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
27	VIM	Vimentin	Protein Coding	10.3	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)

Sources

Variations for Mucinous Adenocarcinoma

Sources

Expression for Mucinous Adenocarcinoma

Search GEO for disease gene expression data for Mucinous Adenocarcinoma.

Sources

Pathways for Mucinous Adenocarcinoma

Pathways related to Mucinous Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 31)

#	Super pathways	Score	Top Affiliating Genes
1	ERK Signaling ⁶³ Show member pathways ILK Signaling ⁶³ MAPK Signaling ⁶³ Molecular Mechanisms of Cancer ⁶³ Rho Family GTPases ⁶³	13.74	TP53 NRG1 MUC1 KRAS HNF4A ESR1
2	Endometrial cancer ³⁶ Show member pathways Acute myeloid leukemia ³⁶ Binding of TCF/LEF-CTNNB1 to target gene promoters ⁶⁵ Chronic myeloid leukemia ³⁶ Colorectal cancer ³⁶ Pancreatic cancer ³⁶ Prostate cancer ³⁶ Signal transduction PTEN pathway ²³ Thyroid cancer ³⁶	12.76	TP53 MLH1 KRAS ERBB2 EGFR CDKN2A
3	Downstream signaling events of B Cell Receptor (BCR) ⁶⁵ Show member pathways Activation of RAS in B cells ⁶⁵ Signaling by the B Cell Receptor (BCR) ⁶⁵	12.68	TP53 NRG1 KRAS ERBB2 EGFR
4	Development HGF signaling pathway ²³ Show member pathways Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1 ²³ Apoptosis and survival NGF signaling pathway ²³ Apoptosis and survival Role of CDK5 in neuronal death and survival ²³ Development Neurotrophin family signaling ²³ MET activates PTPN11 ⁶⁵ MET activates STAT3 ⁶⁵ Neurotrophin signaling pathway ³⁶ Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) ¹ Signaling of Hepatocyte Growth Factor Receptor ¹	12.66	TP53 NRG1 KRAS ESR1 ERBB2
5	Relaxin signaling pathway ³⁶ Show member pathways Estrogen signaling pathway ³⁶ Growth hormone synthesis, secretion and action ³⁶ Relaxin receptors ⁶⁵	12.61	PGR KRT20 KRAS ESR1 EGFR
6	Pathways in cancer ³⁶	12.58	TP53 MLH1 KRAS ESR1 ERBB2 EGFR
7	ErbB signaling pathway ³⁶ ¹ Show member pathways EGFR Inhibitor Pathway, Pharmacodynamics ⁶⁰ EGFR tyrosine kinase inhibitor resistance ³⁶ Renal cell carcinoma ³⁶ TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer ¹	12.54	TP53 NRG1 KRAS ERBB2 EGFR
8	Glioma ³⁶ Show member pathways Endocrine resistance ³⁶ Melanoma ³⁶ Non-small cell lung cancer ³⁶ Signaling Pathways in Glioblastoma ¹	12.47	TP53 KRAS ESR1 ERBB2 EGFR CDKN2A
9	MicroRNAs in cancer ³⁶	12.45	TP53 KRAS ERBB2 EGFR CDKN2A
10	G-protein signaling RAC1 in cellular process ²³ Show member pathways CDC42 signaling events ¹ Cytoskeleton remodeling CDC42 in cellular processes ²³ RAC1 signaling pathway ¹	12.35	NRG1 KRAS ERBB2 EGFR ALK
11	Development Ligand-independent activation of ESR1 and ESR2 ²³ Show member pathways Transcription CREB pathway ²³ Transcription PPAR Pathway ²³	12.27	NRG1 ESR1 ERBB2 EGFR
12	Translation Non-genomic (rapid) action of Androgen Receptor ²³ Show member pathways Basal cell carcinoma ³⁶ Transcription Androgen Receptor nuclear signaling ²³	12.26	TP53 NRG1 ERBB2 EGFR
13	Signaling by ERBB2 ⁶⁵ Show member pathways Downregulation of ERBB2 signaling ⁶⁵ Downregulation of ERBB2-ERBB3 signaling ⁶⁵ ERBB2 Activates PTK6 Signaling ⁶⁵ ERBB2 Regulates Cell Motility ⁶⁵ GRB2 events in ERBB2 signaling ⁶⁵ PI3K events in ERBB2 signaling ⁶⁵ PI3K events in ERBB4 signaling ⁶⁵ SHC1 events in ERBB2 signaling ⁶⁵ SHC1 events in ERBB4 signaling ⁶⁵	12.23	NRG1 KRAS ERBB2 EGFR
14	Proteoglycans in cancer ³⁶	12.19	TP53 KRAS ESR1 ERBB2 EGFR
15	Development ERBB-family signaling ²³ Show member pathways Development EGFR signaling pathway ²³ EGF Pathway ⁶³ ErbB receptor signaling network ¹ GRB7 events in ERBB2 signaling ⁶⁵ PLCG1 events in ERBB2 signaling ⁶⁵	12.17	NRG1 MUC1 KRAS ERBB2 EGFR
16	Colorectal Cancer Metastasis ⁶³	12.12	TP53 MLH1 KRAS EGFR
17	Integrated Breast Cancer Pathway ¹	12.07	TP53 KRAS ESR1 EGFR
18	Tyrosine Kinases / Adaptors ⁴	12.05	NRG1 ERBB2 EGFR ALK
19	Signaling by PTK6 ⁶⁵ Show member pathways PTK6 Activates STAT3 ⁶⁵ PTK6 Down-Regulation ⁶⁵ PTK6 Expression ⁶⁵ PTK6 promotes HIF1A stabilization ⁶⁵ PTK6 Regulates Proteins Involved in RNA Processing ⁶⁵ PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases ⁶⁵ PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 ⁶⁵ RAS signaling downstream of NF1 loss-of-function variants ⁶⁵	11.96	NRG1 KRAS ERBB2 EGFR
20	Gastric cancer ³⁶ Show member pathways Breast cancer ³⁶ Hepatocellular carcinoma ³⁶	11.94	TP53 PGR MLH1 KRAS ESR1 ERBB2
21	DNA Damage Response (only ATM dependent) ¹	11.87	TP53 KRAS ERBB2 CDKN2A
22	Glioblastoma Multiforme ⁶³	11.84	TP53 KRAS EGFR CDKN2A
23	Platinum drug resistance ³⁶	11.62	TP53 MLH1 ERBB2 CDKN2A
24	Central carbon metabolism in cancer ³⁶	11.58	TP53 KRAS ERBB2 EGFR
25	HIF1Alpha Pathway ⁶³	11.53	TP53 HNF4A CDKN2A
26	Photodynamic therapy-induced AP-1 survival signaling. ¹	11.49	TP53 EGFR CDKN2A
27	Signaling by ERBB4 ⁶⁵ Show member pathways Downregulation of ERBB4 signaling ⁶⁵ ErbB4 signaling events ¹ Nuclear signaling by ERBB4 ⁶⁵	11.47	PGR NRG1 KRAS ESR1 ERBB2 EGFR
28	Aryl Hydrocarbon Receptor ¹	11.46	KRAS ESR1 EGFR
29	Agrin Interactions at Neuromuscular Junction ⁶³	11.43	NRG1 KRAS ERBB2 EGFR
30	Bladder cancer ³⁶ ¹	11.42	TP53 KRAS ERBB2 EGFR CDKN2A
31	Extracellular vesicle-mediated signaling in recipient cells ¹	11.18	KRAS ERBB2 EGFR

Sources

GO Terms for Mucinous Adenocarcinoma

Cellular components related to Mucinous Adenocarcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	chromatin	GO:0000785	9.8	TP53 PGR NKX2-1 MUC1 HNF4A ESR1
2	protein-containing complex	GO:0032991	9.63	TP53 ESR1 EGFR CDX2 CDKN2A ALK
3	apical plasma membrane	GO:0016324	9.02	NRG1 MUC1 ERBB2 EGFR CEACAM5
4	intrinsic component of Golgi membrane	GO:0031228	8.96	CHST5 CHST4

Biological processes related to Mucinous Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 21)

#	Name	GO ID	Score	Top Affiliating Genes
1	regulation of transcription by RNA polymerase II	GO:0006357	10.15	TP53 PGR NKX2-1 HNF4A ESR1 ERBB2
2	positive regulation of transcription by RNA polymerase II	GO:0045944	10.08	TP53 PGR NKX2-1 HNF4A ESR1 EGFR
3	positive regulation of protein kinase B signaling	GO:0051897	9.78	NRG1 ESR1 ERBB2 EGFR
4	positive regulation of cell growth	GO:0030307	9.77	NRG1 ERBB2 EGFR
5	positive regulation of kinase activity	GO:0033674	9.74	ERBB2 EGFR ALK
6	Ras protein signal transduction	GO:0007265	9.73	TP53 KRAS CDKN2A
7	positive regulation of MAP kinase activity	GO:0043406	9.69	KRAS ERBB2 EGFR
8	O-glycan processing	GO:0016266	9.67	MUC5AC MUC1 CHST4
9	transmembrane receptor protein tyrosine kinase signaling pathway	GO:0007169	9.67	NRG1 ERBB2 EGFR ALK
10	negative regulation of production of miRNAs involved in gene silencing by miRNA	GO:1903799	9.59	TP53 ESR1
11	positive regulation of RNA polymerase II transcriptional preinitiation complex assembly	GO:0045899	9.58	TP53 ESR1
12	intracellular steroid hormone receptor signaling pathway	GO:0030518	9.58	PGR ESR1
13	positive regulation of transcription from RNA polymerase II promoter in response to stress	GO:0036003	9.52	TP53 MUC1
14	regulation of cell motility	GO:2000145	9.5	NRG1 ERBB2 EGFR
15	negative regulation of ERBB signaling pathway	GO:1901185	9.46	ERBB2 EGFR
16	protein sulfation	GO:0006477	9.43	CHST5 CHST4
17	oligodendrocyte differentiation	GO:0048709	9.43	NRG1 NKX2-1 ERBB2
18	positive regulation of gene expression	GO:0010628	9.43	TP53 NRG1 NKX2-1 KRAS ERBB2 CDKN2A
19	negative regulation of immature T cell proliferation in thymus	GO:0033088	9.4	ERBB2 CDKN2A
20	ERBB2 signaling pathway	GO:0038128	9.33	NRG1 ERBB2 EGFR
21	positive regulation of transcription, DNA-templated	GO:0045893	9.17	TP53 NKX2-1 HNF4A ESR1 EGFR CDX2

Molecular functions related to Mucinous Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 15)

#	Name	GO ID	Score	Top Affiliating Genes
1	identical protein binding	GO:0042802	10.03	TP53 PGR KRAS ESR1 ERBB2 EGFR
2	RNA polymerase II proximal promoter sequence-specific DNA binding	GO:0000978	10.02	TP53 PGR NKX2-1 MUC1 HNF4A ESR1
3	sequence-specific DNA binding	GO:0043565	9.92	PGR NKX2-1 HNF4A ESR1 CDX2
4	chromatin binding	GO:0003682	9.91	TP53 MLH1 HNF4A ESR1 EGFR
5	DNA-binding transcription factor activity	GO:0003700	9.73	TP53 PGR NKX2-1 HNF4A ESR1 CDX2
6	ATPase binding	GO:0051117	9.72	PGR ESR1 EGFR
7	p53 binding	GO:0002039	9.67	TP53 MUC1 CDKN2A
8	MDM2/MDM4 family protein binding	GO:0097371	9.54	TP53 CDKN2A
9	transmembrane receptor protein tyrosine kinase activity	GO:0004714	9.54	ERBB2 EGFR ALK
10	nuclear receptor activity	GO:0004879	9.5	PGR HNF4A ESR1
11	nitric-oxide synthase regulator activity	GO:0030235	9.46	ESR1 EGFR
12	N-acetylglucosamine 6-O-sulfotransferase activity	GO:0001517	9.4	CHST5 CHST4
13	ErbB-3 class receptor binding	GO:0043125	9.16	NRG1 ERBB2
14	steroid hormone receptor activity	GO:0003707	9.13	PGR HNF4A ESR1
15	enzyme binding	GO:0019899	9.1	TP53 PGR NKX2-1 MLH1 ESR1 EGFR

Sources

Sources for Mucinous Adenocarcinoma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GARD

²¹ GeneAnalytics

²² GeneCards

²³ GeneGo (Thomson Reuters)

²⁴ GeneHancer via GeneCards

²⁵ GeneReviews

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ LncRNADisease

³⁹ LOVD

⁴⁰ MalaCards

⁴¹ MedGen

⁴² MedlinePlus

⁴³ MedlinePlus Genetics

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NINDS

⁵⁴ Novoseek

⁵⁵ Novus Biologicals

⁵⁶ OMIM via Orphanet

⁵⁷ OMIM® (Updated 05-Apr-2021)

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubMed

⁶² PubMed Health

⁶³ QIAGEN

⁶⁴ R&D Systems

⁶⁵ Reactome

⁶⁶ Sino Biological

⁶⁷ SNOMED-CT

⁶⁸ SNOMED-CT via HPO

⁶⁹ Tocris

⁷⁰ UMLS

⁷¹ UMLS via Orphanet

⁷² UniProtKB/Swiss-Prot

⁷³ Wikipedia